Reducing the financial impact of pathogen inactivation technology for platelet components: Our experience

Transfusion

Volumn 54, Issue 1, 2014, Pages 158-168

  Girona Llobera, Enrique ^a   Jimenez Marco, Teresa ^a   Galmes Trueba, Ana ^a   Muncunill, Josep ^a   Serret, Carmen ^a   Serra, Neus ^a   Sedeño, Matilde ^a  

^a Fundaciõ Banc de Sang i Teixits de les Illes Balears ^*

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BIOMEDICAL TECHNOLOGY ASSESSMENT; BLOOD COMPONENT; BLOOD SAFETY; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; FEMALE; HEMATOLOGICAL PARAMETERS; HEMATOLOGICAL PROCEDURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL TECHNOLOGY; MIDDLE AGED; PATHOGEN INACTIVATION TECHNOLOGY; RETROSPECTIVE STUDY; SCREENING TEST; THROMBOCYTE; THROMBOCYTE TRANSFUSION;

BLOOD PLATELETS; BLOOD SAFETY; BLOOD-BORNE PATHOGENS; COST SAVINGS; FEMALE; HOSPITALS, UNIVERSITY; HUMANS; MALE; MICROBIAL VIABILITY; MIDDLE AGED; PLATELET TRANSFUSION; PLATELETPHERESIS; RETROSPECTIVE STUDIES; SPAIN;

EID: 84891872378     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12232     Document Type: Article

References (40)

1. Webert KE, Cserti CM, Hannon J, Lin Y, Pavenski K, Pendergrast JM, Blajchman MA,. Proceedings of a Consensus Conference: pathogen inactivation-making decisions about new technologies. Transfus Med Rev 2008; 22: 1-34. (Pubitemid 350193270)
2. Grass JA, Hei DJ, Metchette K, Cimino GD, Wiesehahn GP, Corash L, Lin L,. Inactivation of leukocytes in platelet concentrates by psoralen plus UVA. Blood 1998; 91: 2180-2188. (Pubitemid 28185525)
3. Corash L, Lin L,. Novel processes for inactivation of leukocytes to prevent transfusion-associated graft-versus-host disease. Bone Marrow Transplant 2004; 33: 1-7. (Pubitemid 38159696)
4. Grass JA, Wafa T, Reames A, Wages D, Corash L, Ferrara JL, Lin L,. Prevention of transfusion-associated graft-versus-host disease by photochemical treatment. Blood 1999; 93: 3140-3147. (Pubitemid 29200809)
5. Snyder E, McCullough J, Slichter SJ, Strauss RG, Lopez-Plaza I, Lin JS, Corash L. Conlan MG,. Clinical safety of platelets photochemical treated with amotosalen HCL and ultraviolet A light for pathogen inactivation: the SPRINT trial. Transfusion 2005; 45: 1864-1875. (Pubitemid 43971413)
6. Osselaer JC, Messe N, Hervig T, Bueno J, Castro E, Espinosa A, Accorsi P, Junge K, Jacquet M, Flament J, Corash L,. A prospective observational cohort safety study of 5106 platelet transfusions with components prepared with photochemical pathogen inactivation treatment. Transfusion 2008; 48: 1061-1071. (Pubitemid 351793479)
7. Osselaer JC, Cazenave JP, Lambermont M, Garraud O, Hifajat M, Barbolla L, Tardivel R, Defoin L, Waller C, Mendel I, Raidot JP, Kandel G, De Meuter R, Fabrigli P, Dehenau D, Arroyo JL, Padrõn F, Gouezec H, Corral M, Jacquet M, Sundin D, Lin L, Corash L., An active haemovigilance program characterizing the safety profile of 7437 platelet transfusions prepared with amotosalen photochemical treatment. Vox Sang 2008; 94: 315-323. (Pubitemid 351535733)
8. Cazenave JP, Isola H, Waller C, Mendel I, Kientz D, Laforêt M, Raidot KG, Wiesel ML, Corash L,. Use of additive solutions and pathogen inactivation treatment of platelet components in a regional blood center: impact on patient outcomes and component utilization during a 3-year period. Transfusion 2011; 51: 622-629.
9. TM: a cohort study. Transfus Apher Sci 2011; 45: 175-181.
10. Hei J, Grass J, Lin L, Corash L, Cimino G,. Elimination of cytokine production in stored platelet concentrate aliquots by photochemical treatment with psoralen plus ultraviolet A light. Transfusion 1999; 39: 239-248. (Pubitemid 29144907)
11. Heddle NM, Klama LN, Singer J, Richards C, Fedak P, Walker IR, Kelton JG., The role of plasma from platelets concentrates in transfusion reactions. N Engl J Med 1994; 331: 625-628. (Pubitemid 24276861)
12. Muylle L, Joos M, Wouters E, De Bock R, Peetermans ME,. Increased tumor necrosis factor α (TNFα), interleukin 1, and interleukin 6 (IL-6) levels in the plasma of stored platelet concentrates: relationship between TNFα and IL-6 levels and febrile transfusion reactions. Transfusion 1993; 33: 195-199. (Pubitemid 23073640)
13. Spanish Health Ministry. Royal Decree 1088/2005 of 16 September, laying down the technical requirements and minimum conditions of blood donation and transfusion centers and services. Ministry of Health. Tuesday 20 September 2005. BOE num 225.
14. European Directorate for the Quality of Medicines & HealthCare. Guide for the preparation, use and quality assurance of blood components. 16th ed. Strasbourg: Council of Europe; 2010.
15. McCullough J, Vesole DH, Benjamin RJ, Slichter SJ, Pineda A, Snyder E, Stadtmauer EA, Lopez-Plaza I, Coutre S, Strauss RG, Goodnough LT, Fridey JL, Raife T, Cable R, Murphy S, Howard F, Davis K, Lin JS, Metzel P, Corash L, Koutsoukos A, Lin L, Buchholz D, Conlan MG,. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation treatment: the SPRINT trial. Blood 2004; 104: 1534-1541. (Pubitemid 39166535)
16. Riera C, Fisa R, Lõpez-Chejade P, M Serra T, Girona E, Jiménez M, Muncunill J, Sedeño M, Mascarõ M, Udina M, Gállego M, Carriõ J, Forteza A, Portús M,. Asymptomatic infection by Leishmania infantum in blood donors from the Balearic Islands (Spain). Transfusion 2008; 48: 1383-1389.
17. le Fichoux Y, Quaranta JF, Aufeuvre JP, Lelievre A, Marty P, Suffia I, Rousseau D, Kubar J,. Ocurrence of Leishmania infantum parasitemia in asymptomatic blood donors living in an area of endemicity in southern France. J Clin Microbiol 1999; 37: 1953-1957. (Pubitemid 29235252)
18. Biglio A, Bola C, Concialdi E, Trisciuoglio A, Romano A, Ferroglio E,. Asymptomatic Leishmania infantum infection in an area of north-western Italy (Piedmont region) where such infections are traditionally endemic. J Clin Microbiol 2010; 48: 131-136.
19. Jimenez-Marco T, Fisa R, Riera C, Girona-Llobera E, Sedeño M, Saura A, Iniesta L, Guillen C, Muncunill J,. Pathogen inactivation technology applied to a blood component collected form an asymptomatic carrier of Leishmania infantum: a case report. Vox Sang 2012; 103: 356-358.
20. Benjamin RJ, Stramer SL, Leiby DA, Dodd RY, Fearon M, Castro E,. Trypanosoma cruzi infection in North America and Spain evidence in support of transfusion transmission. Transfusion 2012; 52: 1913-1921.
21. Spanish Association of Haematology and Hemotherapy. Spanish Society of Blood Transfusion. Spanish Accreditation Committee on Transfusion. Accreditation standards for blood transfusion. 3rd ed. 2006 [cited 2012 Aug 1]. Available from: URL: http://www.accionmedica.com/documentos/libros/CAT-TransfSanguinea.pdf
22. Janssen MP, van der Poel CL, Buskens E, Bonneux L, Bonsel GJ, van Hout BA,. Costs and benefits of bacterial culturing and pathogen reduction in the Netherlands. Transfusion 2006; 46: 956-965. (Pubitemid 43800914)
23. Scherenmeier H, Walther-Wenke G, Müller T, Weinauer F, Younis A, Holland-Letz T, Geis G, Asmus J, Bauerfeind U, Burkhart J, Deitenbeck R, Förstemann E, Gebauer W, Höchsmann B, Karakassopoulos A, Loebscher UM, Sänger W, Schmidt M, Schunter F, Sireis W, Siefried E,. Bacterial contamination of platelet concentrates: results of a prospective multicenter study comparing pooled whole blood-derived platelets and apheresis platelets. Transfusion 2007; 47: 644-652. (Pubitemid 46449625)
24. Angelini M, Fressy P, Rasongles P,. Epidémie de Chikungunya à la Réunion et transfusion sanguine. Le Bulletin de l'Hemovigilance de l'Afssaps 2006; 13: 9-10.
25. Bell CE, Botteman MF, Gao X, Weissfeld JL, Postma MJ, Pashos CL, Triulzi D, Staginnus U,. Cost-effectiveness of transfusion of platelet components prepared with pathogen inactivation treatment in the United States. Clin Ther 2003; 25: 2464-2486. (Pubitemid 37267253)
26. Moeremans K, Warie H, Annemans L,. Assessment of the economic value of the INTERCEPT blood system in Belgium. Transfus Med 2006; 16: 17-30.
27. Postma MJ, van Hulst M, De Wolf JT, Botteman M, Staginnus U,. Cost-effectiveness of pathogen inactivation for platelet transfusions in the Netherlands. Transfus Med 2005; 15: 379-387. (Pubitemid 43942845)
28. Staginnus U, Corash L,. Economics of pathogen inactivation technology for platelet concentrates in Japan. Int J Hematol 2004; 80: 317-324. (Pubitemid 39564631)
29. Custer B, Agapova M, Martinez RH,. The cost-effectiveness of pathogen reduction technology as assessed using a multiple risk reduction model. Transfusion 2010; 50: 2461-2473.
30. Osselaer JC, Doyen C, Defoin L, Debry C, Goffaux M, Messe N, van Hooydonk M, Bosly A, Lin JS, Lin L, Corash L,. Universal adoption of pathogen inactivation of platelet components: impact on platelet and red blood cell component use. Transfusion 2009; 49: 1412-1422.
31. Kerkhoffs JL, van Putten W, Novotny V, Te Boekhorst P, Schipperus M, Zwaginga J, van Pampus L, Greef G, Luten M, Huijgens P, Brand A, van Rhenen D,. Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction. Br J Haematol 2010; 150: 209-217.
32. Murphy S, Snyder E, Cable R, Slichter SJ, Strauss RG, McCullough J, Lin JS, Corash L, Conlan M,. Platelet dose consistency and its effect on the number of platelet transfusions for support of thrombocytopenia: an analysis of the SPRINT trial of platelets photochemically treated with amotosalen HCL and ultraviolet A light. Transfusion 2006; 46: 24-33. (Pubitemid 43381781)
33. Lozano M, Knutson N, Tardievel R, Cid J, Maymõ R, Löf HM, Roddie H, Pelly JP, Docherty AR, Sherman CD, Lin L, Propst M, Prowse CV,. A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion. Br J Haematol 2011; 153: 393-401.
34. van Rhenen D, Gulliksson H, Cazenave JP, Pamphilon D, Ljungman P, Klüter H, Vermeij H, Kappers-Klunne M, de Greef G, Laforet M, Lioure B, Davis K, Marblie S, Mayaudon V, Flament J, Conlan MG, Lin L, Metzel P, Buchholz D, Corash L,. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood 2003; 101: 2426-2433. (Pubitemid 36302092)
35. Slichter SJ, Raife TJ, Davis K, Rheinschmidt M, Buchholz DH, Corash L, Conlan MG,. Platelets photochemically treated with amotosalen HCL and ultraviolet A light correct prolonged bleeding times in patients with thrombocytopenia. Transfusion 2006; 46: 731-740.
36. Slichter SJ, Kaufman RM, Assmann SF, McCullough J, Triulzi DJ, Strauss RG, Gernsheimer TB, Ness PM, Brecher ME, Josephson CD, Konkle BA, Woodson RD, Ortel TL, Hillyer CD, Skerrett DL, McCrae KR, Sloan SR, Uhl L, George JN, Aquino VM, Manno CS, McFarland JG, Hess JR, Leissinger C, Granger S,. Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med 2010; 362: 600-613.
37. Vollmer T, Hinse D, Schottstedt V, Bux J, Tapernon K, Sibrowski W, Knabbe C, Dreier J,. Inter-laboratory comparison of different rapid methods for the detection of bacterial contamination in platelet concentrates. Vox Sang 2012; 103: 1-9.
38. Jacobs MR, Smith D, Heaton WA, Zantek ND, Good CE,; PGD Study Group. Detection of bacterial contamination in prestorage culture-negative apheresis platelets on the day of issue with the Pan Genera Detection test. Transfusion 2011; 51: 2573-2582.
39. Vollmer T, Hinse D, Kleesiek K, Dreier J,. The Pan Genera Detection immunoassay: a novel point-of-issue method for detection of bacterial contamination in platelet concentrates. J Clin Microbiol 2010; 48: 3475-3481.
40. Jacobs MR, Good CE, Lazarus HM, Yomtovian RA,. Relationship between bacterial load, species virulence and transfusion reaction with transfusion of bacterially contaminated platelets. Clin Infect Dis 2008; 46: 1214-1220. (Pubitemid 351589905)